(Q48731885)

15 February 2018

title

Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. (English)

1 reference

15 February 2018

0 references

1 reference

T Schneider

1

1 reference

15 February 2018

R Gerhards

series ordinal

2

1 reference

15 February 2018

E Kirches

series ordinal

3

1 reference

15 February 2018

R Firsching

series ordinal

4

1 reference

15 February 2018

publication date

1 May 2001

1 reference

15 February 2018

Journal of Neuro-Oncology

published in

1 reference

15 February 2018

volume

53

1 reference

15 February 2018

issue

1

1 reference

15 February 2018

page(s)

39-46

1 reference

15 February 2018

https://scigraph.springernature.com/pub.10.1023/a:1011856406683

exact match

0 references

cites work

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

1 reference

12 December 2020

Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes

1 reference

12 December 2020

Interferon induction by viruses. X. A model for interferon induction by Newcastle disease virus

1 reference

12 December 2020

Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.

1 reference

12 December 2020

The multi-test system: a standardized approach to evaluation of delayed hypersensitivity and cell-mediated immunity

1 reference

12 December 2020

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

1 reference

12 December 2020

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients

1 reference

12 December 2020

Chemotherapy for malignant gliomas

1 reference

12 December 2020

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

1 reference

12 December 2020

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

1 reference

12 December 2020

In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.

1 reference

12 December 2020

Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta

1 reference

12 December 2020

Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus

1 reference

12 December 2020

Mechanisms by which human gliomas may escape cellular immune attack

1 reference

12 December 2020

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas.

1 reference

12 December 2020

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

1 reference

12 December 2020

Peripheral immunization against malignant rat glioma can induce effective antitumor immunity in the brain.

1 reference

12 December 2020

Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies.

1 reference

12 December 2020

Modulation of T-cell function by gliomas

1 reference

12 December 2020

Relationship of lymphocyte invasion and survival of brain tumor patients

1 reference

12 December 2020

Immunohistochemical analysis of infiltrating lymphocytes in central nervous system tumors.

1 reference

12 December 2020

The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas

1 reference

12 December 2020

Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance

1 reference

12 December 2020

Toxicity determined in vitro by morphological alterations and neutral red absorption

1 reference

12 December 2020

Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.

1 reference

12 December 2020

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity

1 reference

12 December 2020

Generation of cytotoxic immune responses during the progression of a rat glioma.

1 reference

12 December 2020

Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum.

1 reference

12 December 2020

The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture.

1 reference

12 December 2020

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

1 reference

12 December 2020

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

1 reference

12 December 2020

ANTIGENIC SPECIFICITIES ACQUIRED FROM THE GROWTH MEDIUM BY CELLS IN TISSUE CULTURE

1 reference

12 December 2020

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

1 reference

12 December 2020

In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes

1 reference

12 December 2020

Postoperative active specific immunotherapy with supportive measures in patients suffering from recurrent metastasized melanoma: case reports of six patients

1 reference

12 December 2020

Association of malignant glioma with the human leukocyte antigen, HLA-A24(9)

1 reference

12 December 2020

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

1 reference

12 December 2020

Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy

1 reference

12 December 2020

Recent advances in immunobiology of brain tumors

1 reference

12 December 2020

Suppression of anchorage-independent growth of human glioblastoma cell by major histocompatibility complex class I gene-transfection

1 reference

12 December 2020

Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011856406683

1 reference

15 February 2018

Dimensions Publication ID

0 references

1 reference

15 February 2018